CFDE Data Portal | Search RPS3P5

	Label	Description
	RPS3P5 Gene (Entity type)	ENSG00000219755 - ribosomal protein S3 pseudogene 5
	GSE119369 H10 inhibition 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE224105 GSE224108 zearalenone 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE145285 PRMT5 p53 inhibition RNA Messenger 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE52133 LIN-41 knockdown 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Pancreas 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Brain 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx

RPS3P5

ENSG00000219755 - ribosomal protein S3 pseudogene 5

GSE119369 H10 inhibition 3 v 7 human dn

A Gene Set from LINCS

GSE224105 GSE224108 zearalenone 3 v 2 human up

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up

A Gene Set from LINCS

GSE145285 PRMT5 p53 inhibition RNA Messenger 0 v 1 human dn

A Gene Set from LINCS

GSE195568 palbociclib 6 v 0 human dn

A Gene Set from LINCS

GSE239844 crizotinib 6 v 5 human up

A Gene Set from LINCS

GSE52133 LIN-41 knockdown 0 v 2 human dn

A Gene Set from LINCS

GTEx Pancreas 20-29 vs 30-39 Up

A Gene Set from GTEx

GTEx Brain 20-29 vs 30-39 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.